The gains in the global fight against tuberculosis have been threatened as a result of the COVID-19 pandemic, including a diversion of resources that have led to disruptions in ongoing research and control programs.
In a general population of patients with latent TB infection (including patients with and without HIV), studies have confirmed the superior safety profile of treatment with rifampicin vs isoniazid.
Whole genome sequencing of M tuberculosis isolates can identify complete drug susceptibility profiles, allowing precise treatment in early TB infection.
Investigators evaluated the 14-day bactericidal activity of various doses of meropenem, with or without rifampin, in patients being treated for pulmonary tuberculosis.
Researchers evaluated the safety, effectiveness, and cardiotoxity risk associated with concomitant treatment with bedaquiline and delamanid in patients with multidrug-resistant tuberculosis infection.
Investigators at the Centers for Disease Control and Prevention evaluated the effect of a novel 4-month regimen for the treatment of drug-susceptible tuberculosis infection.
Researchers sought to identify the number of patients in Canada with subclinical pulmonary tuberculosis in addition to radiographic and mycobacteriologic features.
Investigators conducted a meta-analysis that compared the safety and efficacy of high-dose rifamycin with standard-dose rifamycin in individuals with active tuberculosis infection.
